Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
2.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
3.
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
4.
Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
5.
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market
6.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
7.
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
8.
Stakeholder Opinions: Heart Failure - When drugs do not work
9.
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
10.
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
Best Sellers:
1.
Primary Brain Cancer
2.
Drug Delivery Global Industry Guide
3.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
4.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
5.
BioNewsCast Press Release Distribution Service
6.
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
7.
Cell Therapy - Technologies, Markets and Companies
8.
Cytogenetics - technologies, markets and companies
9.
Molecular Diagnostics Markets
10.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
Commercial and Pipeline Insight - Systemic antifungals
"IntroductionThe systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.ScopeIn-depth analysis of the market for systemic antifungals covering Japan, US, France, Italy, Germany, Spain and the UK Product by product analysis of the key marketed and pipeline brands that will determine the markets evolution An assessment of key unmet needs and the opportunities they offer for new product development Key considerations for trial design as pre-emptive and targeted strategies replace prophylactic and empiric strategiesHighlightsOver the 2002 to 2006 period, the market for systemic antifungals has risen by a moderate 3.3% from $2.7billion to $3.1 billion; however, its value has dropped by 7.4% between 2005 and 2006. The US and M5EU launch of the next wave of echinocandins (Eraxis and Mycamine) and the next generation azoles (Vfend and Noxafil) will shorten the current period of devaluation of the market caused by widespread uptake of generic fluconazole and itraconazole. New diagnostic technology promises to offer clinicians far better decision making tools, emphasizing the need for a rethink of antifungal clinical trial design. Innovative approaches will be needed to ensure that already costly trials do not become prohibitively expensive, while remaining clinically relevant. Reasons to PurchaseUnderstand clinical and commercial impact of key marketed and pipeline products on the future shape of the systemic fungal infections market Understand the key clinical analysis that will be essential to cater to clinicians information needs and gain widespread use Review the impacts of new diagnostic techniques on antifungal treatment strategies"
14-Nov-07 Format: PDF & SlidePack & DataPack Pages: 393
Table of Contents
Price: $15,200.00 / GBP7,600.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.